
X4 Pharmaceuticals, Inc — Investor Relations & Filings
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | |
| S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339551 | 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | ||
| 42006962 | S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 41806531 | 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 32999251 | ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999249 | DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999239 | DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32963514 | 10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-17 | English | ||
| 30181392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181257 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181249 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181231 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30181103 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 30181313 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 30181211 | SCHEDULE 13G/A Filing | 2026-01-15 | English | ||
| 12390315 | FORM 4 | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-onc…
|
ATORX | SE | Manufacturing |
|
Allmed Medical Products Co., Ltd
Manufacturer of medical dressings, surgical kits, and dispo…
|
002950 | CN | Manufacturing |
|
Allogene Therapeutics, Inc.
Develops off-the-shelf allogeneic CAR T therapies for cance…
|
ALLO | US | Manufacturing |
|
Almirall S.A.
Global biopharmaceutical company specializing in medical de…
|
ALM | ES | Manufacturing |
|
ALNYLAM PHARMACEUTICALS, INC.
A biopharmaceutical company developing RNA interference (RN…
|
ALNY | US | Manufacturing |
|
Alpa Laboratories Limited
WHO-GMP certified manufacturer of human and veterinary phar…
|
ALPA | IN | Manufacturing |
|
Alpha Cognition Inc.
A biopharmaceutical company developing treatments for neuro…
|
ACOG | CA | Manufacturing |
|
Alphamab Oncology
Innovative biopharma specializing in differentiated anti-tu…
|
9966 | KY | Manufacturing |
|
Alpha Teknova, Inc.
Manufacturer of critical reagents for the life sciences ind…
|
TKNO | US | Manufacturing |
|
ALTERITY THERAPEUTICS LTD
A clinical-stage biotech developing novel treatments for ne…
|
ATHE | US | Manufacturing |
X4 Pharmaceuticals, Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34355/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34355 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34355 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34355 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34355}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for X4 Pharmaceuticals, Inc (id: 34355)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.